The biopharmaceutical company which is a spin-out from the University of Bath relocates to the North-East of England.

IP Group, a specialist intellectual property investor, has invested £2m ($3.1m) in Glythera, a biopharmaceutical company specialised in protein functionalisation.

The company is a spin-out from the University of Bath. The deal follows an initial £600,000 investment between IP Group and its fund, the Finance for Business North East Technology Fund.

The following two investments are of a similar size and are dependent on certain milestones.

Glythera has also relocated to the North East of England, appointing David Simpson as chief operating officer.

Duncan Lowery, senior investment manager at IP Group, said: "As David has mentioned, the North East has a real strength in biomanufacturing and the fact that Glythera is relocating here demonstrates that the industry continues to develop and expand apace.

Lowery added: "The technology being developed is highly innovative and could transform the use of vaccines and therapeutics. With a revolutionary product and extremely…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?